Latest placebo Stories

Safinamide Phase III Study Results Presented at 2013 MDS Meeting

2013-06-19 00:20:46

MILAN, June 19, 2013 /PRNewswire/ -- Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD patients as add-on to levodopa Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and...

Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease

2013-06-18 08:30:54

SYDNEY, Australia And EMERYVILLE, Calif., June 18, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia Rating Scale (UDysRS). ADS-5102 is Adamas' investigational extended-release formulation of...

STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis

2013-06-13 08:27:48

Data Show Interleukin-12/23 Inhibitor STELARA Improved Joint, Soft Tissue and Skin Components of Psoriatic Arthritis SPRING HOUSE, Pa., June 13, 2013 /PRNewswire/ -- Results from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 3 study published today in The Lancet showed patients with active psoriatic arthritis who received either STELARA(®) (ustekinumab) 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint compared...

Physiotherapy Patient Interaction Important For Pain Reduction

2013-06-06 11:47:36

University of Alberta How many times have you been to a physiotherapist where you've had more time in the waiting room than face-time with the physio? Well, according to University of Alberta physical therapy PhD grad Jorge Fuentes, how a physiotherapist interacts with a patient verbally, through eye contact, body language and listening skills is almost as important as the treatment itself. "The way we are applying treatment today is not the best approach," Fuentes says. "That might...

RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study in Healthy Volunteers with RXI-109

2013-06-06 08:29:06

RXI-109 was well tolerated and produced a statistically significant and dose dependent reduction of Connective Tissue Growth Factor (CTGF), a protein that causes abnormal scarring when it is over-expressed in a wound WESTBOROUGH, Mass., June 6, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today...

Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80

2013-06-03 23:22:23

Achieve is conducting a Phase 3, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of a new drug for Relief in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time Birmingham, AL (PRWEB) June 03, 2013 INCLUSION CRITERIA Patients may be included in the study if they meet all of the following criteria: 1. The patient has had moderate to severe chronic low back pain for at least 3...

Zensun Announces Positive Clinical Results for Neucardin(TM) to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients

2013-05-23 08:27:51

Clinical program supports accelerated approval filing with CFDA in China, and a Phase 3 program in the U.S. SAN DIEGO and SHANGHAI, May 23, 2013 /PRNewswire/ -- Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun's...

Diabetes Drug Tested In Parkinson's Disease Patients

2013-05-21 08:37:10

Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients. PD...

Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain

2013-05-21 08:28:38

- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p

Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder

2013-05-18 12:20:14

Results Presented at 166th Annual American Psychiatric Association Meeting SAN FRANCISCO, May 18, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration (FDA) for the...